<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CE97FC1C-8B83-431B-8DE7-749A3C4A5F95"><gtr:id>CE97FC1C-8B83-431B-8DE7-749A3C4A5F95</gtr:id><gtr:firstName>Bart</gtr:firstName><gtr:surname>Vanhaesebroeck</gtr:surname><gtr:orcidId>0000-0002-7074-3673</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5306FDC0-04D5-44F0-883E-958AC8C6D682"><gtr:id>5306FDC0-04D5-44F0-883E-958AC8C6D682</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Joel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8236FB4F-D712-44C3-9AFA-FE0E44535C7D"><gtr:id>8236FB4F-D712-44C3-9AFA-FE0E44535C7D</gtr:id><gtr:firstName>Rajesh</gtr:firstName><gtr:surname>Chopra</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/362E9BF7-9AE4-4A89-B26A-E8A3689A67C5"><gtr:id>362E9BF7-9AE4-4A89-B26A-E8A3689A67C5</gtr:id><gtr:firstName>Sylvie</gtr:firstName><gtr:surname>Guichard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/34B35FBE-7059-4725-A2EE-780D38969CD8"><gtr:id>34B35FBE-7059-4725-A2EE-780D38969CD8</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Gribben</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AE62F451-601D-46A9-B89F-D1B0CF4AB378"><gtr:id>AE62F451-601D-46A9-B89F-D1B0CF4AB378</gtr:id><gtr:firstName>Sabina</gtr:firstName><gtr:surname>Cosulich</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E0678D24-9DCD-4BB2-B83F-B6C1260CCCCD"><gtr:id>E0678D24-9DCD-4BB2-B83F-B6C1260CCCCD</gtr:id><gtr:firstName>Pedro</gtr:firstName><gtr:otherNames>Rodriguez</gtr:otherNames><gtr:surname>Cutillas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800914"><gtr:id>CF601756-31F0-42D1-ADA0-18C18EBDBD77</gtr:id><gtr:title>The role of PI 3-kinase/AKT/mTOR and interacting pathways in haematological cancers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800914</gtr:grantReference><gtr:abstractText>In this proposal, the leading pharmaceutical company AstraZeneca teams up with two groups at the Institute of Cancer at St Bartholomew?s Hospital in London, namely the Centre for Experimental Cancer Medicine and the Centre for Cell Signalling. The aim of this proposal is to facilitate the transition of new anti-cancer drugs into the clinic, with a focus on cancer of the white blood cells. The Centre for Experimental Cancer Medicine has a long-standing expertise in both research and clinical trial work in this type of cancer. The Centre for Cell Signalling has world-class expertise in a group of molecules termed PI 3-kinases, which are new targets that AstraZeneca is aiming to block in cancer cells. Together they will provide new methods to assess how blockade of PI 3-kinase will affect the internal wiring of signals that allow cancer cells to survive and multiply. Jointly, the teams are looking for new ways to monitor the impact of drugs againts PI 3-kinases in patient samples, to better assess and predict potential responsiveness, with a view to selecting patients that may respond to these new therapies and to facilitate entry of these potentially new drugs into the clinic.</gtr:abstractText><gtr:technicalSummary>The PI 3-kinase (PI3K)/AKT/mTOR pathway is very frequently deregulated in cancer. Whilst preliminary data implicate this pathway in the pathophysiology of haematological cancers, these data are most often based on cell lines and a small number of clinical samples studied ex vivo. There is therefore a critical need to define the mechanisms by which this pathway is deregulated in primary haematological cancers and in which disease subgroup(s). 
Furthermore there are limited studies that define the role of distinct isoforms of PI3K in haematological cancers, with no data that define the relationship between PI3K protein expression and activity status. This is an important issue in oncology and for the rational application of targeted therapies because protein expression often does not correlate with kinase inhibitor responses. It is therefore important to establish assays and methods that better define pathway activation to identify which patient will benefit from a specific inhibitor.
Focusing on B-cell lymphoma and myeloma, we endeavour to answer these important questions by addressing the following aims:
(1) Define PI3K isoform expression at the protein level, including immunohistochemistry. 
(2) Relate this protein expression profile to the activation status of the Akt and mTOR kinases and other pathway components, by quantitative mass spectrometry, and physiological effects on primary cancer cells
(3) Assess the impact of pathway-specific inhibitors on
(a) in vitro cell survival/proliferation of cancer cells, with or without stromal cells
(b) the activation status of downstream signalling pathways, using quantitative mass spectrometry and other methods
(c) related signalling pathways (inc MEK, JAK/STAT)
(d) gene expression profiles.
These preclinical studies will provide:
(a) novel mechanistic insights into how the PI3K/Akt and mTOR pathway operates and
(b) define activation of key signalling nodes in patient samples and define responses to specific kinase inhibitors, either as monotherapy or in combination
(c) define predictive biomarkers or molecular endpoints in the subsequent clinical evaluation of these agents in haematological cancer. 
These data will be critical for the design and execution of future phase I/II studies in haematological malignancies. Furthermore the focus on primary haematological cancers, with readily available tissue for ex vivo studies, will define exploratory biomarkers and hypotheses that can be further investigated and extrapolated to solid tumours.</gtr:technicalSummary><gtr:fund><gtr:end>2010-11-02</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>445452</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Week Events and Talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BD001F50-BEE4-4C31-A7C5-7B6A2D00CEA0</gtr:id><gtr:impact>Discussion on working in Science - animals in research

various interactions with people interested in science</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab Tours and School Visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DCD4C19A-26AE-4DD8-A401-46A7E1775250</gtr:id><gtr:impact>- over 200 lay people have attended tours in our laboratory
- PI presented the work to over 500 schoolchildren over the period 2007-2012
- PI has hosted placements of pupils in the lab


- PI is asked for return visits every year + additional invitations to talk
- stimulates children to consider careers in science and research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>490000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR Equipment Bid</gtr:description><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>B78F845E-2518-4124-A21D-A8EA9AAB6362</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>138000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Multiple Myeloma Research Fund - Simon Joel</gtr:description><gtr:fundingOrg>Multiple Myeloma Research Foundation</gtr:fundingOrg><gtr:id>7825D496-F716-4420-BF87-B2BB313E401F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Barts and the London Charity - Cutillas, Vanhaesebroeck, Joel et al./Barts and the London Charity</gtr:description><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>8F3CF282-1AF6-4D5E-B469-47BD8EA8D53D</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method to identify which phosphopeptides are amenable to be quantified by mass spectrometry in a global scale and with good accuracy.</gtr:description><gtr:id>45D29F34-8157-4CB2-BA16-8D13A631006E</gtr:id><gtr:impact>The discovery may be important for future bussines of Activiomics, a spin out company from this group.
PATENT APPLICATION TERMINATED 2011</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>GB1006429.3</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Patent application - A method for identifying quantifiable peptides</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New methods for extraction of phosphopeptides - this can be used in bio-marker discovery</gtr:description><gtr:id>006C233B-4044-4578-9927-E6B61E92AFEA</gtr:id><gtr:impact>Licenced to Activiomics Ltd, a spin out company from Barts Cancer Institute, Queen Mary University of London</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Phosphoproteomics assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Activiomics Ltd</gtr:companyName><gtr:description>Activiomics provides a mass spectrometry-based phosphoproteomics service to industry and has in house programs for biomarker discovery and validation.
http://activiomics.com/</gtr:description><gtr:id>2233026C-6355-498B-B6B4-3CD9CC085DC7</gtr:id><gtr:impact>Activiomics Ltd, a new spin-out company from QMUL (2010), funded by the venture capital IP Group and IP Venture fund. Activiomics partners with the pharmaceutical and biotechnology industry to interrogate and interpret the activity of cellular signalling pathways, and to identify biomarkers and drug targets. Activiomics has seen very rapid and significant commercial traction from blue-chip companies, including GlaxoSmithKline, UCB and Genentech, and is scheduled to expand in the near future following recent additional venture capital investment.

Activiomics was acquired by Retroscreen in March 2014</gtr:impact><gtr:url>http://activiomics.com/</gtr:url><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90655779-D59E-4436-9120-A0D9B8D631E6"><gtr:id>90655779-D59E-4436-9120-A0D9B8D631E6</gtr:id><gtr:title>Regulation of p110delta PI 3-kinase gene expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dfc033a1f35778d43c7e98214534c4a7"><gtr:id>dfc033a1f35778d43c7e98214534c4a7</gtr:id><gtr:otherNames>Kok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59AC041C-1C69-44D8-89DC-683F360B6062"><gtr:id>59AC041C-1C69-44D8-89DC-683F360B6062</gtr:id><gtr:title>Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A4E2368-07EB-462A-A42A-1273ABE0BE50"><gtr:id>6A4E2368-07EB-462A-A42A-1273ABE0BE50</gtr:id><gtr:title>Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cfa50226ff64a6956cb752e82827bdad"><gtr:id>cfa50226ff64a6956cb752e82827bdad</gtr:id><gtr:otherNames>Rajeeve V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F022A53-897B-49E6-B3CA-1D404F78C434"><gtr:id>0F022A53-897B-49E6-B3CA-1D404F78C434</gtr:id><gtr:title>Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04ab8d573b12f52ecc1c48766b9f8100"><gtr:id>04ab8d573b12f52ecc1c48766b9f8100</gtr:id><gtr:otherNames>Casado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27FBD110-AE33-44A8-8FB2-CE8F76B443D8"><gtr:id>27FBD110-AE33-44A8-8FB2-CE8F76B443D8</gtr:id><gtr:title>Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6884b61d279f8c13088c17cfb32c2bc"><gtr:id>e6884b61d279f8c13088c17cfb32c2bc</gtr:id><gtr:otherNames>Montoya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17710273-3C94-4962-8DBD-398E66505DBD"><gtr:id>17710273-3C94-4962-8DBD-398E66505DBD</gtr:id><gtr:title>A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04ab8d573b12f52ecc1c48766b9f8100"><gtr:id>04ab8d573b12f52ecc1c48766b9f8100</gtr:id><gtr:otherNames>Casado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD6D335E-F707-49AB-AA2A-4352E7A2D26C"><gtr:id>FD6D335E-F707-49AB-AA2A-4352E7A2D26C</gtr:id><gtr:title>Advances in phosphopeptide enrichment techniques for phosphoproteomics.</gtr:title><gtr:parentPublicationTitle>Amino acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0939-4451</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87118C95-900E-41F1-9083-52BD356AFD88"><gtr:id>87118C95-900E-41F1-9083-52BD356AFD88</gtr:id><gtr:title>Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4c1e0bfb643645f3be9f9b905e054fb"><gtr:id>c4c1e0bfb643645f3be9f9b905e054fb</gtr:id><gtr:otherNames>Papakonstanti EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE701A2F-BB7D-4F8C-BA08-25E576BEAB66"><gtr:id>DE701A2F-BB7D-4F8C-BA08-25E576BEAB66</gtr:id><gtr:title>Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/efe96f4fdd8f749f95da88d18fd41b7f"><gtr:id>efe96f4fdd8f749f95da88d18fd41b7f</gtr:id><gtr:otherNames>Alcolea MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38BA4588-AD1D-4659-A50A-4DB62365A9B4"><gtr:id>38BA4588-AD1D-4659-A50A-4DB62365A9B4</gtr:id><gtr:title>Global profiling of protein kinase activities in cancer cells by mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800914</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>